BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Qualyst, Inc. Announces Oversubscribed Closing Of Its Series B Financing And The Continued Expansion Of Its Client Base


5/3/2006 10:38:57 AM

RESEARCH TRIANGLE PARK, N.C., May 3 /PRNewswire/ -- Qualyst, Inc. today announced that it has accomplished the closing of its Series B Preferred Stock Offering, bringing total funds raised through the Series A and Series B financing rounds to $5.5 million. Specific financial details relating to Series B were not disclosed. Burton Advisers Ltd. (of London) acted as the exclusive advisor and financial arranger for the Offering.

Scott Neuville, President and CEO, commented, "Our Series B Preferred Stock Offering was oversubscribed due to investor demand. A large number of Series A investors participated in Series B, and we are delighted that our investors continue to recognize the value of Qualyst's proprietary technologies for drug research and development."

Neuville added, "Qualyst's compelling products have helped secure additional relationships with some of the world's most respected pharmaceutical and biotechnology companies."

Qualyst also confirmed the granting of the patent for B-CLEAR(R) in Europe. B-CLEAR(R) is now patented in the United States and Europe, with additional patents issued and pending worldwide.

About Qualyst, Inc.

Qualyst commercializes novel and proprietary ADMET products for drug discovery and development. Qualyst's products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process. Qualyst, Inc. was founded on discoveries from breakthrough research in the School of Pharmacy at the University of North Carolina at Chapel Hill in 2001. For additional information, please refer to the company's web site at http://www.qualyst.com or call 919-313-6500.

Qualyst, Inc.

CONTACT: Scott E. Neuville, President and CEO of Qualyst, Inc.,info@qualyst.com, or +1-919-313-6501



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES